Figure 4From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedsideEfficacy of ABT-869 in representative xenografts. Efficacy was defined as percent of tumor size relative to vehicle-treated remaining after 3–4 weeks of dosing ABT-869 (10–25 mg/kg/day).Back to article page